Relapse HISTORY for her2+S

[RobinP]

http://www.what-is-cancer.com/papers...recurrence.htm


THE ABOVE LINK IS ANNUAL RISK OF RECURRENCE FOR VARIOUS GROUPS, NOT SPECIFICALLY ADDRESSING HER2 GROUPS. HOWEVER, STILL THIS GRAPH IS HELPFUL IN TERMS OF REFLECTING GENERAL HORMONAL POSITIVE AND NEGATIVE RELAPSE.

[stephanie59]

You all have me very confused. Let me see if I understand: statistically are you saying that HER2+ER-PR- relapses long term less than HER2+ER+PR- breast cancers? Or is it the other way around?

After reading posts for the last week or so, I started to worry about lower back pain I have been experiencing for the last few months. Have not had blood work since last November so have no indication if tumor marker is up. My oncologist is scheduling me for a bone scan asap. This is not the way I wanted to get Herceptin (not eligible before). Hope it's just old age catching up with me. Keep fingers crossed. Stephanie

[sassy]

My onc and I have discussed the possibility of long term heart impact, and the fact that statistical data is not available because previously long term use had not been expected due to underestimated effect of Herceptin. Could you share where I might find the documentation of 2 year info being available in April 2007, with release not scheduled until 2008? You are a wealth of information and I appreciate all your help and support!
________
SweetBlackAss3010

[sarah]

I've been on Herceptin 18 months. There's something about being ER+ and HER2+ that needs balancing or it up ticks the other, so it seems you need to take an AI with Herceptin? So I'm on Herceptin and Femara. Really not sure how well researched this is.
sarah

[Hopeful]

sarahdalton, here is a link to an article that explores the issue of her2/endocrine therapy: http://erc.endocrinology-journals.or.../full/11/4/623. I will be doing Femara + Herceptin, also; currently doing Rx + Herceptin.

Hopeful

[Lani]

since writing that article Dr. Nicholson has written 24 more. If there are any die-hards who really want to know all the latest before making up their minds (and these are only his articles and there are scores writing on it, but he and Dr. Dowsett seem to be the most interested in this, I supply the following list of references--due to technical problems (my computer ignorance). I will list about 4 and then about another 20 in a second post):
21: Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, Duncan R. Related Articles, Links
Polymer therapeutics designed for a combination therapy of hormone-dependent cancer.
Angew Chem Int Ed Engl. 2005 Jun 27;44(26):4061-6. No abstract available.
PMID: 15912547 [PubMed - in process]
22: Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D, Gee JM. Related Articles, Links
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):257-62. Epub 2005 Feb 8. Review.
PMID: 15860268 [PubMed - indexed for MEDLINE]
23: Taylor KM, Morgan HE, Johnson A, Nicholson RI. Related Articles, Links
Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14.
FEBS Lett. 2005 Jan 17;579(2):427-32.
PMID: 15642354 [PubMed - indexed for MEDLINE]
24: Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI. Related Articles, Links
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
Endocr Relat Cancer. 2004 Dec;11(4):793-814.
PMID: 15613453 [PubMed - indexed for MEDLINE]

[Lani]

1: Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, Gee JM, Nicholson RI, Lykkesfeldt AE, Shousha S, Coombes RC, Ali S. Related Articles, Links
Phosphorylation of ER{alpha} at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER{alpha} phosphorylation in breast cancer progression.
Endocr Relat Cancer. 2006 Sep;13(3):851-61.
PMID: 16954434 [PubMed - in process]
2: Jones HE, Gee JM, Barrow D, Tonge D, Holloway B, Nicholson RI. Related Articles, Links
Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.
Br J Cancer. 2006 Jul 17;95(2):172-80. Epub 2006 Jul 4.
PMID: 16819546 [PubMed - in process]
3: Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA. Related Articles, Links
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.
Cancer Res. 2006 Jun 1;66(11):5950-9.
PMID: 16740736 [PubMed - indexed for MEDLINE]
4: De Martino G, Edler MC, La Regina G, Coluccia A, Barbera MC, Barrow D, Nicholson RI, Chiosis G, Brancale A, Hamel E, Artico M, Silvestri R. Related Articles, Links
New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies.
J Med Chem. 2006 Feb 9;49(3):947-54.
PMID: 16451061 [PubMed - indexed for MEDLINE]
5: Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Related Articles, Links
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Breast Cancer Res Treat. 2006 Jun;97(3):263-74. Epub 2005 Dec 7.
PMID: 16333527 [PubMed - in process]
6: Greco F, Vicent MJ, Penning NA, Nicholson RI, Duncan R. Related Articles, Links
HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.
J Drug Target. 2005 Sep-Nov;13(8-9):459-70.
PMID: 16332571 [PubMed - indexed for MEDLINE]
7: Yee SW, Jarno L, Gomaa MS, Elford C, Ooi LL, Coogan MP, McClelland R, Nicholson RI, Evans BA, Brancale A, Simons C. Related Articles, Links
Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays.
J Med Chem. 2005 Nov 17;48(23):7123-31.
PMID: 16279770 [PubMed - indexed for MEDLINE]
8: Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI. Related Articles, Links
Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Breast Cancer Res Treat. 2006 Mar;96(2):131-46. Epub 2005 Oct 27.
PMID: 16261397 [PubMed - in process]
9: Dowsett M, Nicholson RI, Pietras RJ. Related Articles, Links
Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
Breast Cancer Res Treat. 2005;93 Suppl 1:S11-8. Review.
PMID: 16247595 [PubMed - indexed for MEDLINE]
10: Nicholson RI, Johnston SR. Related Articles, Links
Endocrine therapy--current benefits and limitations.
Breast Cancer Res Treat. 2005;93 Suppl 1:S3-10. Review.
PMID: 16247594 [PubMed - indexed for MEDLINE]
11: Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. Related Articles, Links
Clinical value of epidermal growth factor receptor expression in primary breast cancer.
Adv Anat Pathol. 2005 Sep;12(5):271-3. Review.
PMID: 16210923 [PubMed - indexed for MEDLINE]
12: Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI. Related Articles, Links
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111. Review.
PMID: 16113104 [PubMed - indexed for MEDLINE]
13: Staka CM, Nicholson RI, Gee JM. Related Articles, Links
Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S85-97.
PMID: 16113102 [PubMed - indexed for MEDLINE]
14: Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM. Related Articles, Links
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S29-36. Review.
PMID: 16113097 [PubMed - indexed for MEDLINE]
15: Duncan R, Vicent MJ, Greco F, Nicholson RI. Related Articles, Links
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S189-99. Review.
PMID: 16113096 [PubMed - indexed for MEDLINE]
16: Jones HE, Gee JM, Taylor KM, Barrow D, Williams HD, Rubini M, Nicholson RI. Related Articles, Links
Development of strategies for the use of anti-growth factor treatments.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S173-82. Review.
PMID: 16113094 [PubMed - indexed for MEDLINE]
17: Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Related Articles, Links
Overview of tyrosine kinase inhibitors in clinical breast cancer.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S135-44. Review.
PMID: 16113090 [PubMed - indexed for MEDLINE]
18: Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M, Barrett-Lee P, Robertson JF, Johnston SR, Jones HE, Wakeling AE, Duncan R, Nicholson RI. Related Articles, Links
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S1-7. Review.
PMID: 16113086 [PubMed - indexed for MEDLINE]
19: Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI. Related Articles, Links
Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.
Int J Cancer. 2006 Jan 15;118(2):290-301.
PMID: 16080193 [PubMed - indexed for MEDLINE]
20: Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Related Articles, Links
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
Endocrinology. 2005 Nov;146(11):4609-18. Epub 2005 Jul 21.
PMID: 16037379 [PubMed - indexed for MEDLINE]
Items 1 - 20 of 211

Hope this helps!

[gin-tx]

Dear Sarah,

I too was diagnosed Her 2, second episode of BC, first 10 yrs ago. Don' t know all the details of the tumor but need to find out more when I see my onc in two weeks. I too am on Herceptin/Aridia (for bones) and Femora. So far it appears to be working okay, am having CT to see if tumor that was on my spine is gone from 18 treatments of radiation (that had to be dealt with first, malignant) and a mammogram next month. Let me know how you continue to do on the Herceptin. I've only had 5 treatments with no side effects except very tired.

hugs,

ginkott1@aol.com

[SusanV]

Just asked my onc today about taxol....with herceptin. His response was that there is minimal value for er+'s like myself......

Alaska Angel had posted this same info...just wanted to give you what my onc said today !

Love to All

[Bev]

Hi Susan V, I think I would get a second opinion. Panel F shows recurrence at 5 years at 10% with T & H. 30% without. My doc said the absolute reduction in risk after doing tamox, rads etc for Herceptin is 5%. My doc recommended doing it, The only difference in pathology between me and you is 1.6cm. You're younger and high grade. I think I would push for some Herceptin.

Thanks all for your posts. I know the graphs are just numbers but I like having them. The discussion makes everything so much easier to understand.